Rani Therapeutics (RANI) said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable "bioavailability, pharmacokinetics, and weight loss to subcutaneous administration."
The company said the new data adds to the "growing body of evidence" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.
The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.
Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.
Price: 2.05, Change: +0.61, Percent Change: +42.36
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。